

5. (Amended Twice) A non transgenic mouse mammary adenocarcinoma cell line, wherein the cell line is selected from the group consisting of MC4-L1 (ATCC# PTA-889), MC4-L3 (ATCC# PTA-891), MC4-L2 (ATCC# PTA-892) and MC7-L1 (ATCC # PTA-890).
7. (Amended) A non-transgenic mouse mammary adenocarcinoma cell line system for testing the activity of a hormone, an anti-hormone, a pharmacological compound and an environmental agent, wherein the system comprises a cell line selected from the group consisting of MC4-L1 (ATCC# PTA-889), MC4-L3 (ATCC# PTA-891), MC4-L2 (ATCC# PTA-892) and MC7-L1 (ATCC # PTA-890) cell line.
8. (Amended) An *in vitro* method for testing the activity of a hormone, an anti-hormone, a pharmacological compound or an environmental agent, comprising the steps of:
- cultivating a cell line system, wherein the cell line system comprises a cell line selected from the group consisting of MC4-L1 (ATCC# PTA-889), MC4-L3 (ATCC# PTA-891), MC4-L2 (ATCC# PTA-892) and MC7-L1 (ATCC # PTA-890);
- exposing the cell line system to the hormone, the anti-hormone, the pharmacological compound, or the environmental agent; and
- quantifying cell proliferation.
11. (Amended Twice) A kit for determining the effect of a hormone, anti-hormone, pharmacological compounds and environmental agents, wherein the kit comprises an aliquot of a cell line selected from the group consisting of MC4-L1 (ATCC# PTA-889), MC4-L3 (ATCC# PTA-891), MC4-L2 (ATCC# PTA-892) and MC7-L1 (ATCC # PTA-890) and a method for evaluating the proliferation of cells.